A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients withC9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) - WVE-004-002
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) - WVE-004-001
100 项与 Wave Life Sciences UK Ltd. 相关的临床结果
0 项与 Wave Life Sciences UK Ltd. 相关的专利（医药）
100 项与 Wave Life Sciences UK Ltd. 相关的药物交易
100 项与 Wave Life Sciences UK Ltd. 相关的转化医学
